论文部分内容阅读
Dofetilide来自索他洛尔分子的非β阻滞部分,动物实验证明,它具有高度特异性Ⅲ类抗心律失常药活性;而无Ⅰ、Ⅱ或Ⅳ类活性。 18例稳定型心绞痛,分三组(每组6例),分别静脉滴注Dofetilide小剂量、大剂量或安慰剂。Dofetilide小剂量为负荷量3μg/kg,15分钟滴完;继以维持量1.5μg/kg,45分钟滴完。大剂量为负荷量5μg/kg,15分钟滴完;继以维持量2.5μg/kg,45分钟滴完。滴注前后作电生理和12导心电图。结果发现,Dofetilide使心房有效不应期延长10～23％(P<0.05),功能不应期延长14～22％(P<0.05);心室有效不应期延长
Dofetilide comes from the non-beta block of sotalol, which has been shown in animal experiments to possess highly specific class III antiarrhythmic activity without class I, II or IV activity. Eighteen patients with stable angina pectoris were divided into three groups (6 in each group), and received intravenous Dofetilide, low-dose, high-dose or placebo respectively. Dofetilide low dose of 3μg / kg load, drip finished 15 minutes; followed by the maintenance dose 1.5μg / kg, 45 minutes dripping finished. Large dose of 5μg / kg load, drip 15 minutes; followed by the maintenance dose 2.5μg / kg, 45 minutes dripping finished. Before and after the infusion for electrophysiology and 12-lead ECG. The results showed that Dofetilide prolongs the effective refractory period by 10-23% (P <0.05), prolongs the refractory period by 14-22% (P <0.05), prolongs the effective ventricular refractory period